It all started with a mundane phonecall in August, received by the Noida office of a Swiss-Indian drug company called Naari. The caller, a Calcutta-based Indian businessman called Chris Harris, wanted samples of a drug called sodium thiopental to dispatch, he explained, to Zambia for registration by the country’s drug authorities. It was a perfectly plausible request. The drug, though largely replaced by better anaesthetics in the West, is still used widely in the developing world. Accordingly, Naari dipped into its stocks and sent vials containing 485 grams of sodium thiopental to Harris in Calcutta in end-September; and waited for the large order that he said would follow.
A few weeks later, the firm’s Indian officials were stunned when an investigator with the London-based charity, Reprieve, which campaigns against the death penalty, called to tell them where those samples had really gone. Not to Zambia, but the American state of Nebraska; not for medicinal use, but to execute convicts by the chosen American method, lethal injection (see infographic).
Surprise turned to outrage when they learnt from the investigator, Maya Foa, that Naari had even been named as the supplier of the drug in a press release issued by Nebraska’s Department of Correctional Services (NCDs) on November 3. “We’re not in the business of helping to execute people, we were lied to and cheated,” says a spokesman for the company. The prison paid $5,411 for the chemicals—over 15 times what Naari would have ordinarily charged Harris for them. But Harris hadn’t paid at all. By selling Naari’s free samples to Nebraska’s execution machinery, apparently desperate for drugs, the small-time middleman had made—yes—a killing.
Foa, who’s working with Naari on strategies to prevent the exported drugs being used in executions, says the episode, though shocking, is typical. “It is often the case that manufacturers and suppliers are drawn into this trade unwittingly and have no idea their drugs are going to execution chambers,” she says. That knowledge belongs to perfidious middlemen, key players in a macabre niche of global commerce ominously seeking to widen its footprint in India.
The intriguing larger question is: why are state institutions in the mighty United States shopping at the murky end of the pharma trade? The answer is, they don’t have much choice. Drug companies, increasingly reluctant to be branded as suppliers of drugs for lethal injections, are distancing themselves from US prisons, which is no small achievement for hyperactive anti-capital punishment groups. When Hospira, the sole producer of sodium thiopental within the US, shut shop in 2009, for a variety of reasons, some US prisons initially managed to source the drug from Britain. (By now, it will not surprise readers to know it came from a company that operated out of the back of a driving school.) However, campaigners put an end to that trade by persuading several European governments to ban it. Many US prisons switched to a single drug called pentobarbital, commonly used to put down dogs, but campaigners won that round, too. In July this year, a Danish company, Lundbeck, the only licensed maker of the drug in the US, bowed to pressure (especially when it took the form of a major investor, a Danish pension fund, selling off a hefty € 5.4 million worth of its shares) and agreed to deny the drug to American execution chambers.
What has made the campaign against lethal injection popular is not just European aversion to the death penalty, but the campaigners’ unrelenting focus on American double standards. The US Food and Drug Administration (USFDA) zealously protects its citizens from the perceived shortcomings of foreign drugs (ask big Indian pharmaceutical firms, which have to jump through many hoops for usfda approval, before their products can enter the US market) but those standards drop dramatically, clearly for political reasons, when it comes to the import of drugs for lethal injections. That’s why consignments arranged by Indian middlemen are able to make it to US prisons.
The tacit rationale seems to be that standards don’t matter for people who will die anyway. But lawyers and campaigners are contesting that cynical argument, both in and outside the courts. They argue that murky supply chains can result in chemicals becoming degraded and lead to torturous and painful deaths. The chilling, oft-cited recent case is of Brandon Rhode, 31, whose eyes remained open until he died, leading a doctor to testify that the imported (from Britain) sodium thiopental injected into him may have “lacked efficiency”.
While campaigners are all set to fight the use of the latest imports for executions, the Indian route is a worry, admits Foa. “We have been very successful; some US states are now in a de facto state of moratorium on the death penalty. This could take us backwards.”
Should Indians care? Opinions are divided, even among those who usually care, reflecting cleavages on the larger question of capital punishment. (There is also a certain exasperation with the blinkered, single-issue vision of western groups.) C.M. Gulhati, usually a trenchant critic of drug companies, sees no case to answer here. “If we execute our prisoners, we really can’t object to Americans executing theirs. There are no legal, clinical or ethical grounds on which we can say, don’t export the drug to American prisons,” he says. Amar Jesani, an expert on ethics, rights and health systems, disagrees: “What is lawful is not necessarily ethical. Section 377 was not ethical, the death penalty is not.” Pointing out that doctors in America do not, by consensus, administer lethal injections, he says: “If they don’t participate in killing, pharmaceutical companies shouldn’t either. They should be named and shamed when they do.”
Interestingly, Dilip G. Shah, secretary general of the Indian Pharmaceutical Alliance, takes much the same tack. Dismissively, he says, “This is a niche segment, dominated by unscrupulous small operators looking for easy money. None of the large pharmaceutical companies would touch it. They wouldn’t want to be associated with killing people.” And why, he asks, should the industry compromise on its reputation for relatively small gains: “The volume is nothing—are there that many people on death row?” For campaigners, that last argument might work best, in persuading India to turn its back on this sordid trade. Self-interest usually gets more done than ethics.
Does the media want to incite Indians into enter into the debate over the larger issue of death penalty?
Other than that, this is merely an issue of exporting what is necessary for another country - in this case, a drug.
So finally Indian products are being used to kill Americans! The revenge for Bhopal is long overdue!
Wonder why Chinese are not in this business yet?
Alfred Hitchcock once wrote an essay in defence of Evil. He said that Evil does not get a fair hearing, nobody knows the good that it does. Death creates space for life, destruction creates space for new things, pain makes us wise, personal troubles give rise to forbearance, war releases energies to do good and so on.
In the spirit of that Devil's advocate, here goes.
How does it matter that somebody sells a drug which is used to kill people according to the law of a different land. Should we then ban sale of butcher's knives, hangman's nooses, sleeping pills (barbituates), chloroform etc on the ground that somebody is using it for "bad" purposes. How about stopping any work on prison constructions and improvements. Why not terminate all vultures because they prey on carcasses? If the middleman makes a killing in the trade, is that any business of moralists who may not be saints with impeccable good thoughts/behavior? Did he activley kill, or merely supplied something an authority asked for?
It is over-simplistic to moralize on things over which we have no control, or an end-result which does not affect us in any way.
JHUMRI TALAIYYA, INDIA
Right, you are!
IF the media wants a debate on death penalty, why does nt it state so DIRECTLY instead of resorting to indirect means as the feminists are wont to do?
We at Outlookindia.com welcome feedback and your comments, including scathing criticism
1. Scathing, passionate, even angry critiques are welcome, but please do not indulge in abuse and invective. Our Primary concern is to keep the debate civil. We urge our users to try and express their disagreements without being disagreeable. Personal attacks are not welcome. No ad hominem please.
2. Please do not post the same message again and again in the same or different threads
3. Please keep your responses confined to the subject matter of the article you are responding to. Please note that our comments section is not a general free-for-all but for feedback to articles/blogs posted on the site
4. Our endeavour is to keep these forums unmoderated and unexpurgated. But if any of the above three conditions are violated, we reserve the right to delete any comment that we deem objectionable and also to withdraw posting privileges from the abuser. Please also note that hate-speech is punishable by law and in extreme circumstances, we may be forced to take legal action by tracing the IP addresses of the poster.
5. If someone is being abusive or personal, or generally being a troll or a flame-baiter, please do not descend to their level. The best response to such posters is to ignore them and send us a message at Mail AT outlookindia DOT com with the subject header COMPLAINT
6. Please do not copy and paste copyrighted material. If you do think that an article elsewhere has relevance to the point you wish to make, please only quote what is considered fair-use and provide a link to the article under question.
7. There is no particular outlookindia.com line on any subject. The views expressed in our opinion section are those of the author concerned and not that of all of outlookindia.com or all its authors.
8. Please also note that you are solely responsible for the comments posted by you on the site. The comments could be deleted or edited entirely at our discretion if we find them objectionable. However, the mere fact of their existence on our site does not mean that we necessarily approve of their contents. In short, the onus of responsibility for the comments remains solely with the authors thereof. Outlookindia.com or any of its group publications, may, however, retains the right to publish any of these comments, with or without editing, in any medium whatsoever. It is therefore in your own interest to be careful before posting.
9.Outlookindia.com is not responsible in any manner whatsoever for how any search engine -- such as Google, Bing etc -- caches or displays these comments. Please note that you are solely responsible for posting these comments and it is a privilege being granted to our registered users which can be withdrawn in case of abuse. To reiterate:
a. Comments once posted can only be deleted at the discretion of outlookindia.com
b. The comments reflect the views of the authors and not of outlookindia.com
c. outlookindia.com is not responsible in any manner whatsoever for the way search engines cache or display these comments
d. Please therefore take due caution before you post any comments as your words could potentially be used against you
10. We have an online thread for our comments policy:
You are welcome to post your suggestions here or in case you have a specific issue, to directly email us at Mail AT outlookindia DOT com with the subject header COMPLAINT